Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis

Oncoimmunology. 2022 Aug 1;11(1):2104070. doi: 10.1080/2162402X.2022.2104070. eCollection 2022.

Abstract

Bone disease represents a major cause of morbidity and mortality in Multiple Myeloma (MM); primarily driven by osteoclasts whose differentiation is dependent on expression of RANKL by MM cells. Notably, costimulation by ITAM containing receptors (i.e., FcγR) can also play a crucial role in osteoclast differentiation. Modeling the pathology of the bone marrow microenvironment with an ex vivo culture system of primary human multiple myeloma cells, we herein demonstrate that FcγR-mediated signaling, via staphylococcal protein A (SpA) IgG immune-complexes, can act as a critical negative regulator of MM-driven osteoclast differentiation. Interrogation of the mode-of-action revealed that FcγR-mediated signaling causes epigenetic modulation of chromosomal 3D architecture at the RANK promoter; with altered spatial orientation of a proximal super enhancer. Combined this leads to substantial down-regulation of RANK at a transcript, protein, and functional level. These observations shed light on a novel mechanism regulating RANK expression and provide a rationale for targeting FcγR-signaling for the amelioration of osteolytic bone pathology in disease.

Keywords: FcγR; RANK; epigenetic; multiple myeloma; osteoclasts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation / genetics
  • Humans
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / metabolism
  • Osteoclasts / metabolism
  • Osteogenesis* / genetics
  • Receptors, IgG / genetics
  • Receptors, IgG / metabolism
  • Tumor Microenvironment

Substances

  • Receptors, IgG